Targeted cancer therapy based on blocking the expression of genes and small doses of oxaliplatin.
Poster Apr 01, 2014
Bavykin A.S.1, Korotaeva A.A.1, Poyarkov S.V.2, Syrtsev A.V.1, Karpukhin A.V.1
Results. We found that colon cancer cells HCT-116, when exposed to low concentrations of oxaliplatin (5 and 10mkM) showed the the same survival rate as for the untreated cells, however their expression patterns were different. We examined the panel of genes with various functions in the presence of small dozes of oxaliplatin and picked up those, that displayed marked overexpression and were depended both on the oxaliplatin dose escalation and the incubation period. These genes belong to the family of inhibitors of apoptosis and associated with the caspase cascade. Shutting down the expression of these genes was performed using short interfering RNAs (siRNAs), attached to the liposome particles. These ultra – small molecules can suppress synthesis of desired proteins at the level of messenger RNA of Birc3 and Birc7 genes. Due to the ultra small size, and low concentration, that is sufficient enough to inhibit protein synthesis at an early stage. Thus siRNA have considerable advantages compared with targeted antibodies.
Conclusion. Identified target genes Birc3 and Birc7 display specific response to oxaliplatin treatment. Joint inhibiting the synthesis of these genes resulted in virtually complete (85%, p<0,05) suppression of the viability of cancer cells and increased (7-fold) sensitivity of cancer cells to low doses of oxaliplatin.
Applications of chemically modified synthetic guide RNA for CRISPR-Cas9 genome editingPoster
Our results indicate that MS modifications are required for experiments with co-electroporation of Cas9 mRNA and synthetic gRNA, yet have no impact on editing efficiency when delivered with lipid-based transfection reagents.READ MORE
Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell LinesPoster
Inecalcitol is a vitamin D receptor agonist currently in Phase II clinical trial in AML (acute myeloid leukemia). Inecalcitol increases the expression of CD38 at the surface of 5 multiple myeloma cell lines; therefore, inecalcitol could potentiate the clinical response of MM patients to a therapeutic anti-CD38 antibody
Inecalcitol induces the expression of the CD38 antigen at the surface of 4 AML cell lines; thus, inecalcitol could render AML patients sensitive to a therapeutic anti-CD38.
Strategies for Improving RNAi Screening Success: Using a Ubiquitin-EGFP Assay to Identify Druggable Genes Required for Proteasome FunctionPoster
This poster describes the approaches used to ensure effective delivery of siRNA molecules and to identify robust siRNA controls. It also provides the strategies used to validate compatibility of the RNAi automation platform with the phenotype being analyzed.READ MORE